Home › Funds › Royce & Associates › ATNM
Royce & Associates position in ATNM
ACTINIUM PHARMACEUTICALS INC · Health Care
Latest position (Q3 2024)50.00K sh
Reported value held$94.00K
Portfolio Weight0.00%
First reportedQ1 2023
Last changeHold
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2023 | 50.00K | $473 | New |
| Q2 2023 | 50.00K | $371.00K | Hold |
| Q3 2023 | 50.00K | $296.00K | Hold |
| Q4 2023 | 50.00K | $254.00K | Hold |
| Q1 2024 | 50.00K | $391.50K | Hold |
| Q2 2024 | 50.00K | $370.00K | Hold |
| Q3 2024 | 50.00K | $94.00K | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
Other funds holding ATNM
- Vanguard Group 1.42M sh · $1.93M · Q4 2025
- Millennium Management 514.58K sh · $504.29K · Q2 2026
- BlackRock Inc 395.90K sh · $387.98K · Q2 2026
- Renaissance Technologies 380.49K sh · $372.88K · Q2 2026
- Geode Capital Management 324.94K sh · $318.55K · Q2 2026
- Two Sigma Investments 259.18K sh · $254.00K · Q2 2026
- Northern Trust Corp 69.74K sh · $68.35K · Q2 2026
- Wells Fargo & Co 19.80K sh · $19.40K · Q2 2026
- UBS Group AG 6.76K sh · $6.62K · Q2 2026
- Morgan Stanley 6.34K sh · $6.21K · Q2 2026
- JPMorgan Chase & Co 1.49K sh · $1.48K · Q2 2026